- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04160156
Long-term, Implantable Sensor Improves Health Outcomes in Patients With T1D
November 8, 2019 updated by: Concetta Irace, University Magna Graecia
Clinical Use of the Long-term Implantable Sensor Improves Glycated Hemoglobin and Time in Range in Patients With Type 1 Diabetes
The implantable Eversense ® CGM System obtained CE marking in 2016 for the 90-day device and in 2017 for the 180-day device.There is interest in real-world clinical evidence on the use of Eversense regarding changes in HbA1c and time in range (TIR), time below range (TBR), and time above range (TAR) in patients with type 1 diabetes.
This is a prospective, multi-center, observational clinical study among adult participants aged 18 years or older with T1D and Eversense CGM System-naïve aimed to evaluate the change in HbA1c and glucometric parameters (TIR, TAR, TBR, mean daily glucose and standard deviation) in patients with T1D from multiple clinics in Italy using the Eversense CGM System for a 6-month time period.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A new continuous glucose monitoring system (CGM), the Eversense ® CGM System (Company Senseonics, Inc., location of Company Germantown, MD) has been developed and commercially introduced in the last 3 years.
This system may overcome drawbacks and limitations of traditional transcutaneous CGM systems.
It consists of a fully implantable sensor lasting up to 180 days, a removable smart transmitter providing unique on-body vibratory alerts, and a mobile medical app (MMA) displaying glucose information captured and calculated by the transmitter.
The app generates pop-up messages and alerts for glucose values crossing low and high thresholds, rate of change of glucose exceeding pre-set limits, and predicted low and high glucose levels.
Glucose data are uploaded and stored in the cloud.
Data from the cloud can be analyzed to provide different glucometric parameters such as time in range (TIR, 70-180 mg/dL), time below range (TBR, <70mg/dL), time above range (TAR, >180 mg/dL), mean daily glucose levels, and standard deviation (SD).
The safety and accuracy of the new system has been evaluated in the PRECISE, PRECISE II and the PRECISION studies.
The accuracy of the system is very high and no serious adverse events and very few adverse events have been reported in pivotal trials.
Among adverse events, redness/erythema, bruising and pain at the sensor insertion site occurred.
The purpose of this analysis will be to evaluate the change in HbA1c and in glucometric parameters, such as TIR, TBR, TAR, mean daily glucose, and SD in patients with T1D from multiple clinics in Italy using the Eversense CGM System for a 6-month time period.
This is a prospective, multi-center, observational clinical research study among adult participants aged 18 years or older with T1D across several diabetes-care centers in Italy.
Patients will be required to be Eversense CGM System-naïve.
Patients will be trained on the Eversense CGM System use before sensor insertion, as suggested by the current clinical practice recommendations.
Specifically, they will be instructed about the principles of the sensor technology, the operational aspects of the device, and the interpretation of displayed data.
No specific therapeutic recommendations will be suggested to adjust pre-meal insulin dosing.
Patients will be advised to take an action when alerts will be asserted, according to general recommendations, including checking the glucose value using a traditional blood glucose meter.
The following parameters will be collected for each patient: HbA1c (measured using high-performance liquid chromatography) within two months before sensor implantation and 6 months after the implantation, disease duration, prior use of CGM, and insulin therapy delivery mode (MDI or CSII).
The Eversense CGM System consists of an implantable, fluorescence-based, long-term sensor; the smart transmitter worn on top of the skin above the sensor; and the medical mobile app (MMA) which operates on a mobile device (smart phone, smart watch, or iPad) and provides real-time monitoring of current and historical glucose values.
The long-term sensor will be implanted by trained endocrinologists into the subcutaneous tissue of the upper arm at the end of the deltoid muscle in all patients.
Patients will be registered in the Eversense Data Management System (DMS) allowing automatic uploading of sensor glucose data.
Study participants will be followed according to local practice.
The euglycemic target (TIR, glucose 70-180 mg/dL), TAR (glucose >180 mg/dL), TBR (glucose <70 mg/dL), mean overall daily glucose, and mean SD, will be collected from the DMS over the first 2 weeks after the first sensor implantation (baseline) and 2 weeks before the 6-month visit.
HbA1c and CGM metric changes in patients using CSII and MDI treatment for insulin delivery, and in patients who were CGM-naïve and prior CGM users will be assessed to observe the differences by prior CGM use and method of insulin delivery.
Specifically, patients will be categorized into four different subgroups: CSII and prior CGM use, CSII and CGM naïve, MDI and prior CGM use, and MDI and CGM naïve.
Appropriate tests will be performed using SPSS (Statistical Package for Social Science) 23 for Macintosh.
Variables not normally distributed will be analyzed with non parametric test or if necessary a 2-step rank transformation will be applied to normalize the variables.
All patients will be informed about the finality of the research and they will be required to give informed consent in order to analyze data collected by the DMS.
They will receive all scheduled visits according to clinical practice.
Study Type
Observational
Enrollment (Actual)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Catanzaro, Italy, 88100
- University Magna Graecia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Adult participants aged 18 years or older who were suggested to wear long term sensor.
Description
Inclusion Criteria:
- Type 1 diabetes
- Age >18 years
- Eversense ® CGM System-naïve
Exclusion Criteria:
- candidates for a MRI during sensor wear
- critically ill including hospitalization
- known contradiction to dexamethasone
- required intravenous mannitol or mannitol irrigation solutions
- pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Type 1 diabetes
Subjects attending metabolic clinic who were suggested to use long term sensor due to persistent hyperglycemia and hypoglycemia
|
Observational study including subjects using long term sensor according to local guidelines and patients preferences
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HbA1c (%)
Time Frame: six months
|
Measured by High Performance Liquid Chromatography
|
six months
|
Time in Range (%)
Time Frame: six months
|
Collection from diabetes management system
|
six months
|
Time Below Range (%)
Time Frame: six months
|
Collection from diabetes management system
|
six months
|
Time Above Range (%)
Time Frame: six months
|
Collection from diabetes management system
|
six months
|
Mean Daily Glucose (mmol/l)
Time Frame: six months
|
Collection from diabetes management system
|
six months
|
Glucose Standard Deviation (mmol/L)
Time Frame: six months
|
Collection from diabetes management system
|
six months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 5, 2018
Primary Completion (Actual)
June 30, 2019
Study Completion (Actual)
June 30, 2019
Study Registration Dates
First Submitted
November 7, 2019
First Submitted That Met QC Criteria
November 8, 2019
First Posted (Actual)
November 12, 2019
Study Record Updates
Last Update Posted (Actual)
November 12, 2019
Last Update Submitted That Met QC Criteria
November 8, 2019
Last Verified
November 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Long term implantable sensor
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on Long term sensor
-
Ukraine Association of BiobankActive, not recruitingDiabete Type 2 | Mesenchymal Stem CellUkraine
-
Helsinki University Central HospitalCompleted
-
Mental Health Services in the Capital Region, DenmarkUniversity of Copenhagen; Copenhagen Trial Unit, Center for Clinical Intervention...Completed
-
Sun Yat-sen UniversityUnknownMultifocal Contact LensesChina
-
University of BernCompletedDental Implants | PeriimplantitisSwitzerland
-
Haukeland University HospitalOslo University Hospital; University Hospital of North Norway; Helse Stavanger... and other collaboratorsRecruitingNervous System Diseases | Neurodegenerative Diseases | Motor Neuron Disease | Amyotrophic Lateral Sclerosis | Spinal Cord Diseases | TDP-43 ProteinopathiesNorway
-
City of Hope Medical CenterActive, not recruiting
-
Blue Note TherapeuticsEnrolling by invitation
-
Novindiet ClinicTehran University of Medical Sciences; University of NottinghamCompletedObesity | OverweightIran, Islamic Republic of
-
Buchinger Wilhelmi Development & Holding GmbHKing's College London; University of Geneva, Switzerland; ETH Zurich (Switzerland) and other collaboratorsCompletedHealthy | PeriodontitisGermany